RBC Capital analyst Arun Viswanathan downgraded Pactiv Evergreen (PTVE) to Sector Perform from Outperform with a price target of $18, up from $14, after the company entered into an agreement to merge with Novolex for $18 per share. RBC views the stock as fairly valued at current levels, noting the acquisition by Novolex has shareholder approval.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTVE: